KRAS and hypertensive disorder: No statistically significant differences were found between the two groups in terms of hypertension, peritoneal metastasis, carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 125(CA125), KRAS gene mutation, BRAF gene mutation, TP53 gene mutation, or chemotherapy regimen (Table 2).